New synaptic and molecular targets for neuroprotection in Parkinson's disease
Corresponding Author
Paolo Calabresi MD
Clinical Neurology, University of Perugia, Perugia, Italy
IRCCS, Santa Lucia Foundation, Rome, Italy
Correspondence to: Professor Paolo Calabresi, Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, 06156 Perugia, Italy; [email protected]Search for more papers by this authorMassimiliano Di Filippo MD
Clinical Neurology, University of Perugia, Perugia, Italy
IRCCS, Santa Lucia Foundation, Rome, Italy
Search for more papers by this authorAntongiulio Gallina MD
Clinical Neurology, University of Perugia, Perugia, Italy
Search for more papers by this authorYingfei Wang PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorJeannette N. Stankowski PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorBarbara Picconi PhD
Clinical Neurology, University of Perugia, Perugia, Italy
IRCCS, Santa Lucia Foundation, Rome, Italy
Search for more papers by this authorValina L. Dawson PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorTed M. Dawson MD, PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorCorresponding Author
Paolo Calabresi MD
Clinical Neurology, University of Perugia, Perugia, Italy
IRCCS, Santa Lucia Foundation, Rome, Italy
Correspondence to: Professor Paolo Calabresi, Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, 06156 Perugia, Italy; [email protected]Search for more papers by this authorMassimiliano Di Filippo MD
Clinical Neurology, University of Perugia, Perugia, Italy
IRCCS, Santa Lucia Foundation, Rome, Italy
Search for more papers by this authorAntongiulio Gallina MD
Clinical Neurology, University of Perugia, Perugia, Italy
Search for more papers by this authorYingfei Wang PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorJeannette N. Stankowski PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorBarbara Picconi PhD
Clinical Neurology, University of Perugia, Perugia, Italy
IRCCS, Santa Lucia Foundation, Rome, Italy
Search for more papers by this authorValina L. Dawson PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorTed M. Dawson MD, PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorFunding agencies: This work was supported by grants from European Community contract number 222918 (REPLACES) FP7—Thematic priority HEALTH (PC), and Progetto Giovani Ricercatori Ministero Sanità 2008 (BP).
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
Abstract
The defining anatomical feature of Parkinson's disease (PD) is the degeneration of substantia nigra pars compacta (SNc) neurons, resulting in striatal dopamine (DA) deficiency and in the subsequent alteration of basal ganglia physiology. Treatments targeting the dopaminergic system alleviate PD symptoms but are not able to slow the neurodegenerative process that underlies PD progression. The nucleus striatum comprises a complex network of projecting neurons and interneurons that integrates different neural signals to modulate the activity of the basal ganglia circuitry. In this review we describe new potential molecular and synaptic striatal targets for the development of both symptomatic and neuroprotective strategies for PD. In particular, we focus on the interaction between adenosine A2A receptors and dopamine D2 receptors, on the role of a correct assembly of NMDA receptors, and on the sGC/cGMP/PKG pathway. Moreover, we also discuss the possibility to target the cell death program parthanatos and the kinase LRRK2 in order to develop new putative neuroprotective agents for PD acting on dopaminergic nigral neurons as well as on other basal ganglia structures. © 2013 Movement Disorder Society
References
- 1Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010; 9: 1106–1117.
- 2Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 2004; 3: 309–316.
- 3Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol. 2008; 64( Suppl 2): S101–S110.
- 4Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience. 2005; 132: 741–754.
- 5Deutch AY. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease. J Neural Transm Suppl. 2006: 67–70.
- 6Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008; 70: 1916–1925.
- 7Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci. 2006; 9: 251–259.
- 8Villalba RM, Smith Y. Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys. J Comp Neurol. 2011; 519: 989–1005.
- 9Villalba RM, Smith Y. Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease. Front Syst Neurosci. 2011; 5: 68.
- 10Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997; 20: 482–487.
- 11Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007; 83: 277–292.
- 12Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol. 2007; 83: 293–309.
- 13Vallano A, Fernandez-Duenas V, Pedros C, Arnau JM, Ciruela F. An update on adenosine A2A receptors as drug target in Parkinson's disease. CNS Neurol Disord Drug Targets. 2011; 10: 659–669.
- 14Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther. 2005; 105: 267–310.
- 15Mishina M, Ishiwata K, Naganawa M, et al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS One. 2011; 6: e17338.
- 16Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011; 76: 1811–1816.
- 17Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis. 2010; 20( Suppl 1): S205–S220.
- 18Flajolet M, Wang Z, Futter M, et al. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat Neurosci. 2008; 11: 1402–1409.
- 19Song BW, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther. 2002; 301: 605–610.
- 20Tozzi A, Tscherter A, Belcastro V, et al. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology. 2007; 53: 783–789.
- 21Tozzi A, de Iure A, Di Filippo M, et al. The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease. J Neurosci. 2011; 31: 1850–1862.
- 22Peterson JD, Goldberg JA, Surmeier DJ. Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion. Neurobiol Dis. 2011; 45: 409–416.
- 23Gubellini P, Picconi B, Di Filippo M, Calabresi P. Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. Biochim Biophys Acta. 2010; 1802: 151–161.
- 24Schapira AH. Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol. 2010; 224: 331–335.
- 25Belcastro V, Tozzi A, Tantucci M, et al. A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol. 2009; 217: 231–234.
- 26Calabresi P, Di Filippo M. Neuroscience: brain's traffic lights. Nature. 2010; 466: 449.
- 27Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007; 30: 211–219.
- 28Calabresi P, Pisani A, Mercuri NB, Bernardi G. Long-term Potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur J Neurosci. 1992; 4: 929–935.
- 29Lovinger DM. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology. 2010; 58: 951–961.
- 30Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B. Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans. 2010; 38: 493–497.
- 31Pisani A, Centonze D, Bernardi G, Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord. 2005; 20: 395–402.
- 32Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol. 2000; 47(4 Suppl 1): S60–S68; discussion S68–S69.
- 33Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003; 6: 501–506.
- 34Ghiglieri V, Sgobio C, Costa C, Picconi B, Calabresi P. Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. Prog Neurobiol. 2011; 94: 102–114.
- 35Picconi B, Passino E, Sgobio C, et al. Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. Neurobiol Dis. 2006; 22: 143–152.
- 36Ghiglieri V, Picconi B, Sgobio C, et al. Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. Eur J Neurosci. 2009; 29: 1979–1993.
- 37Ghiglieri V, Sgobio C, Patassini S, et al. TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid. Neuropsychopharmacology. 2010; 35: 1531–1540.
- 38Calabresi P, Centonze D, Pisani A, Cupini L, Bernardi G. Synaptic plasticity in the ischaemic brain. Lancet Neurol. 2003; 2: 622–629.
- 39Di Filippo M, Tozzi A, Costa C, et al. Plasticity and repair in the post-ischemic brain. Neuropharmacology. 2008; 55: 353–362.
- 40Picconi B, Tortiglione A, Barone I, et al. NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke. 2006; 37: 1895–1901.
- 41Di Filippo M, Tozzi A, Ghiglieri V, et al. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. Biol Psychiatry. 2010; 67: 666–671.
- 42Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci. 2007; 8: 803–808.
- 43Gardoni F, Ghiglieri V, Luca M, Calabresi P. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Prog Brain Res. 2010; 183: 169–182.
- 44Picconi B, Gardoni F, Centonze D, et al. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci. 2004; 24: 5283–5291.
- 45Anglade P, Mouatt-Prigent A, Agid Y, Hirsch E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration. 1996; 5: 121–128.
- 46Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol. 2004; 187: 76–85.
- 47Bagetta V, Picconi B, Marinucci S, et al. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci. 2011; 31: 12513–12522.
- 48Centonze D, Gubellini P, Picconi B, Calabresi P, Giacomini P, Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol. 1999; 82: 3575–3579.
- 49Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007; 445: 643–647.
- 50Tang K, Low MJ, Grandy DK, Lovinger DM. Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci U S A. 2001; 98: 1255–1260.
- 51Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114: 2283–2301.
- 52Paille V, Picconi B, Bagetta V, et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci. 2010; 30: 14182–14193.
- 53Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002; 298: 846–850.
- 54Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci. 2006; 26: 2914–2922.
- 55Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging. 2011 [Epub ahead of print].
- 56Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog Brain Res. 1998; 118: 215–229.
- 57Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 1995; 18: 527–535.
- 58Calabresi P, Gubellini P, Centonze D, et al. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci. 1999; 19: 2489–2499.
- 59Del Bel EA, Guimaraes FS, Bermudez-Echeverry M, et al. Role of nitric oxide on motor behavior. Cell Mol Neurobiol. 2005; 25: 371–392.
- 60West AR, Tseng KY. Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson's disease? Front Syst Neurosci. 2011; 5: 55.
- 61Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect. 1994; 7: 115–121.
- 62Eve DJ, Nisbet AP, Kingsbury AE, et al. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res. 1998; 63: 62–71.
- 63Sancesario G, Giorgi M, D'Angelo V, et al. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci. 2004; 20: 989–1000.
- 64Giorgi M, D'Angelo V, Esposito Z, et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci. 2008; 28: 941–950.
- 65Picconi B, Bagetta V, Ghiglieri V, et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain. 2011; 134: 375–387.
- 66Tozzi A, Costa C, Siliquini S, et al. Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol Aging. 2012; 33: 1792–1799.
- 67Hara MR, Thomas B, Cascio MB, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006; 103: 3887–3889.
- 68David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci. 2009; 14: 1116–1128.
- 69Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol. 2009; 218: 193–202.
- 70Dawson VL, Dawson TM. Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr. 2004; 36: 287–294.
- 71Wang Y, Kim NS, Haince JF, et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal. 2011; 4: ra20.
- 72Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol. 2008; 173: 2–13.
- 73Andrabi SA, Kim NS, Yu SW, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A. 2006; 103: 18308–18313.
- 74Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem. 1993; 122: 171–193.
- 75Smulson ME, Simbulan-Rosenthal CM, Boulares AH, et al. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul. 2000; 40: 183–215.
- 76Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A. 1999; 96: 5774–5779.
- 77Outeiro TF, Grammatopoulos TN, Altmann S, et al. Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Biochem Biophys Res Commun. 2007; 357: 596–602.
- 78Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 2002; 297: 259–263.
- 79Cheung EC, Melanson-Drapeau L, Cregan SP, et al. Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. J Neurosci. 2005; 25: 1324–1334.
- 80Culmsee C, Zhu C, Landshamer S, et al. Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci. 2005; 25: 10262–10272.
- 81Chu CT, Zhu JH, Cao G, Signore A, Wang S, Chen J. Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells. J Neurochem. 2005; 94: 1685–1695.
- 82Andrabi SA, Kang HC, Haince JF, et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med. 2011; 17: 692–699.
- 83Kang HC, Lee YI, Shin JH, et al. Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proc Natl Acad Sci U S A. 2011; 108: 14103–14108.
- 84Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006; 60: 557–569.
- 85Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. 2010; 11: 791–797.
- 86Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006; 29: 286–293.
- 87Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta. 2009; 1792: 625–633.
- 88Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 2010; 16: 998–1000.
- 89Nichols RJ, Dzamko N, Hutti JE, et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J. 2009; 424: 47–60.
- 90Deng X, Dzamko N, Prescott A, et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 2011; 7: 203–205.
- 91Dzamko N, Deak M, Hentati F, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14–3-3 binding and altered cytoplasmic localization. Biochem J. 2010; 430: 405–413.
- 92Ramsden N, Perrin J, Ren Z, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011; 6: 1021–1028.
- 93Liu Z, Hamamichi S, Lee BD, et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet. 2011; 20: 3933–3942.
- 94Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol. 2011; 12: 1063–1070.
- 95MC, Kolly C, Persohn E, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 2011; 20: 4209–4223.
- 96Tong Y, Yamaguchi H, Giaime E, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A. 2011; 107: 9879–9884.